The world’s COVID-19 vaccine distribution has shown the strengths and weaknesses of today’s supply chains. Healthcare companies pioneering cell and gene therapies—which rely on human cellular material—need to pay particular attention to lessons learned as they face unique supply chain challenges of their own. It all starts with planning.
Supply chains are helping distribute life-saving vaccines, but they’re also needed to help get the economy back to normal. We need to do both, but it won’t be easy.
As major pharma players—including Pfizer, J&J, Gilead, Moderna and AstraZeneca—announce vaccines for the COVID-19 virus that’s claimed over 1.3 million lives, life sciences companies have an increased focus on delivering their vaccines to millions—potentially billions—of people.
At the center of the COVID-19 storm, most healthcare providers generally did an exemplary job transitioning operations from on-premises to work-from-home. But that may have been the easy part.
Supply chain expert Ron Rod details how healthcare providers, payers and life sciences companies are responding to COVID-19 supply chain interruptions while preparing to emerge stronger in the future.
Meet and greet us at an upcoming event!
Als globales Beratungsunternehmen betreuen wir Kunden auf der ganzen Welt. Dementsprechend ist unsere Website in englischer Sprache verfasst. Sie können uns jederzeit auch auf Deutsch kontaktieren, indem Sie sich an unsere Standorte in Hamburg und Zürich wenden. Besuchen Sie gerne auch unsere LinkedIn-Seite von RGP Deutschland.
